Boris Peaker
Stock Analyst at TD Cowen
(2.49)
# 1,257
Out of 4,479 analysts
19
Total ratings
30%
Success rate
9.21%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Downgrades: Hold | n/a | $4.30 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $80.00 | +25.00% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $3.68 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $28.46 | +75.69% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $76.94 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $19.02 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $7.06 | +310.76% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $1.33 | - | 1 | Jul 11, 2022 | |
| MRK Merck & Co. | Maintains: Market Perform | $95 → $102 | $127.90 | -20.25% | 1 | Jun 27, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $1.22 | - | 1 | Mar 15, 2022 | |
| NCNA NuCana | Downgrades: Market Perform | n/a | $2.77 | - | 1 | Mar 3, 2022 | |
| AADI Aadi Bioscience | Initiates: Outperform | n/a | $1.42 | - | 1 | Oct 1, 2021 | |
| TCRX TScan Therapeutics | Initiates: Outperform | n/a | $5.93 | - | 1 | Aug 13, 2021 | |
| CELC Celcuity | Initiates: Outperform | n/a | $16.64 | - | 1 | Jul 29, 2021 | |
| STRO Sutro Biopharma | Initiates: Outperform | n/a | $3.05 | - | 1 | Oct 22, 2018 | |
| MRSN Mersana Therapeutics | Initiates: Outperform | n/a | $1.97 | - | 1 | Jul 24, 2017 | |
| ARGX argenx SE | Initiates: Outperform | n/a | $434.22 | - | 1 | Jun 12, 2017 |
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.30
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $80.00
Upside: +25.00%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.68
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $28.46
Upside: +75.69%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $76.94
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $19.02
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $7.06
Upside: +310.76%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Merck & Co.
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $127.90
Upside: -20.25%
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.22
Upside: -
NuCana
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.77
Upside: -
Aadi Bioscience
Oct 1, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.42
Upside: -
TScan Therapeutics
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.93
Upside: -
Celcuity
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $16.64
Upside: -
Sutro Biopharma
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $3.05
Upside: -
Mersana Therapeutics
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.97
Upside: -
argenx SE
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $434.22
Upside: -